Back to results
US 11,746,158 B2Granted
Therapeutic molecules
AssigneeCrescendo Biologics Limited
InventorsBrian McGuinness, Isabelle Osuch, Chris Rossant, Mike Romanos, Nikki Royle, Thomas Sandal, Lorraine Thompson, Michele Writer
Life of this patent
Estimating the term…
Abstract
The invention relates to binding molecules that bind specifically to prostate specific membrane antigen (PSMA), in particular, single human variable heavy chain domain antibodies and related methods for treatment of cancer.
Claims12
A binding molecule capable of binding human PSMA comprising a single human variable heavy chain domain (VH) antibody comprising CDR1, CDR2 and CDR3 sequences selected from
- a CDR1 sequence comprising SEQ ID NO. 1, a CDR2 sequence comprising SEQ ID NO. 2 and a CDR3 sequence comprising SEQ ID NO. 3, or
- a CDR1 sequence comprising SEQ ID NO. 5, a CDR2 sequence comprising SEQ ID NO. 6 and a CDR3 sequence comprising SEQ ID NO. 7, or
- a CDR1 sequence comprising SEQ ID NO. 9, a CDR2 sequence comprising SEQ ID NO. 10 and a CDR3 sequence comprising SEQ ID NO. 11, or
- a CDR1 sequence comprising SEQ ID NO. 13, a CDR2 sequence comprising SEQ ID NO. 14 and a CDR3 sequence comprising SEQ ID NO. 15, or
- a CDR1 sequence comprising SEQ ID NO. 17, a CDR2 sequence comprising SEQ ID NO. 18 and a CDR3 sequence comprising SEQ ID NO. 19, or
- a CDR1 sequence comprising SEQ ID NO. 21, a CDR2 sequence comprising SEQ ID NO. 22 and a CDR3 sequence comprising SEQ ID NO. 23, or
- a CDR1 sequence comprising SEQ ID NO. 25, a CDR2 sequence comprising SEQ ID NO. 26 and a CDR3 sequence comprising SEQ ID NO. 27, or
- a CDR1 sequence comprising SEQ ID NO. 29, a CDR2 sequence comprising SEQ ID NO. 30 and a CDR3 sequence comprising SEQ ID NO. 31, or
- a CDR1 sequence comprising SEQ ID NO. 33, a CDR2 sequence comprising SEQ ID NO. 34 and a CDR3 sequence comprising SEQ ID NO. 35, or
- a CDR1 sequence comprising SEQ ID NO. 37, a CDR2 sequence comprising SEQ ID NO. 38 and a CDR3 sequence comprising SEQ ID NO. 39, or
- a CDR1 sequence comprising SEQ ID NO. 41, a CDR2 sequence comprising SEQ ID NO. 42 and a CDR3 sequence comprising SEQ ID NO. 43, or
- a CDR1 sequence comprising SEQ ID NO. 45, a CDR2 sequence comprising SEQ ID NO. 46 and a CDR3 sequence comprising SEQ ID NO. 47, or
- a CDR1 sequence comprising SEQ ID NO. 49, a CDR2 sequence comprising SEQ ID NO. 50 and a CDR3 sequence comprising SEQ ID NO. 51, or
- a CDR1 sequence comprising SEQ ID NO. 53, a CDR2 sequence comprising SEQ ID NO. 54 and a CDR3 sequence comprising SEQ ID NO. 55, or
- a CDR1 sequence comprising SEQ ID NO. 57, a CDR2 sequence comprising SEQ ID NO. 58 and a CDR3 sequence comprising SEQ ID NO. 59, or
- a CDR1 sequence comprising SEQ ID NO. 61, a CDR2 sequence comprising SEQ ID NO. 62 and a CDR3 sequence comprising SEQ ID NO. 63, or
- a CDR1 sequence comprising SEQ ID NO. 65, a CDR2 sequence comprising SEQ ID NO. 66 and a CDR3 sequence comprising SEQ ID NO. 67, or
- a CDR1 sequence comprising SEQ ID NO. 69, a CDR2 sequence comprising SEQ ID NO. 70 and a CDR3 sequence comprising SEQ ID NO. 71, or
- a CDR1 sequence comprising SEQ ID NO. 73, a CDR2 sequence comprising SEQ ID NO. 74 and a CDR3 sequence comprising SEQ ID NO. 75, or
- a CDR1 sequence comprising SEQ ID NO. 77, a CDR2 sequence comprising SEQ ID NO. 78 and a CDR3 sequence comprising SEQ ID NO. 79.
17 more elements
Dependencies are inferred from the claim text.